Zeria Pharmaceutical Co Ltd - Product Pipeline Review - H2 2011
Global Markets Direct
November 28, 2011 58 Pages - SKU: GMD6692639
|
|
Zeria Pharmaceutical Co Ltd - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Zeria Pharmaceutical Co Ltd - Product Pipeline Review - H2 2011” provides data on the Zeria Pharmaceutical Co Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Zeria Pharmaceutical Co Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from Zeria Pharmaceutical Co Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - Zeria Pharmaceutical Co Ltd - Brief Zeria Pharmaceutical Co Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Zeria Pharmaceutical Co Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Zeria Pharmaceutical Co Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Zeria Pharmaceutical Co Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate Zeria Pharmaceutical Co Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Zeria Pharmaceutical Co Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Zeria Pharmaceutical Co Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Zeria Pharmaceutical Co Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Zeria Pharmaceutical Co Ltd and identify potential opportunities in those areas.
|
- Zeria Pharmaceutical Co Ltd Snapshot
- Zeria Pharmaceutical Co Ltd Overview
- Key Information
- Key Facts
- Zeria Pharmaceutical Co Ltd - Research and Development Overview
- Key Therapeutic Areas
- Zeria Pharmaceutical Co Ltd - Pipeline Review
- Pipeline Products by Stage of Development
- Zeria Pharmaceutical Co Ltd - Pipeline Products Glance
- Zeria Pharmaceutical Co Ltd - Late Stage Pipeline
- Registration Filed Products/Combination Treatment Modalities
- Phase III Products/Combination Treatment Modalities
- Zeria Pharmaceutical Co Ltd Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Zeria Pharmaceutical Co Ltd - Drug Profiles
- Z-100
- Z-103
- Z-206
- Z-207
- Z-208
- Z-338
- Z-360
- Z-360 + Gemcitabine
- Z-521
- Zeria Pharmaceutical Co Ltd - Pipeline Analysis
- Zeria Pharmaceutical Co Ltd - Pipeline Products by Therapeutic Class
- Zeria Pharmaceutical Co Ltd - Pipeline Products By Target
- Zeria Pharmaceutical Co Ltd - Pipeline Products by Route of Administration
- Zeria Pharmaceutical Co Ltd - Pipeline Products by Molecule Type
- Zeria Pharmaceutical Co Ltd - Recent Pipeline Updates
- Zeria Pharmaceutical Co Ltd - Dormant Projects
- Zeria Pharmaceutical Co Ltd - Discontinued Pipeline Products
- Discontinued Pipeline Product Profiles
- Z-100
- Zeria Pharmaceutical Co Ltd - Company Statement
- Zeria Pharmaceutical Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Sep 29, 2010: Zeria And Astellas Pharma Submit NDA Of Z-338 /YM443 For Functional Dyspepsia In Japan
- Jun 28, 2010: Zeria Announces Positive Phase III Trial Results Of Z-338 In Dyspepsia
- Jun 28, 2010: Zeria Announces Positive Results From Phase III Study Of Z-338 For Functional Dyspepsia Conducted In Japan
- Financial Deals Landscape
- Zeria Pharmaceutical Co Ltd, Deals Summary
- Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details
- Partnerships
- HemCon Medical Technologies Signs Licensing Agreement With Zeria Pharmaceuticals
- Augurix Enters Into Co-Marketing Agreement With Tillotts Pharma
- Cambrex Enters Into Co-Development Agreement With Tillotts Pharma
- Zeria Pharmaceutical Enters Into Agreement With Astellas Pharma
- Tillotts Pharma Enters Into Research Collaboration Agreement With University of London
- Zeria Pharmaceutical Enters Into Co-Development Agreement With TMRC
- Tillotts Pharma Enters Into Development And Marketing Agreement With Zeria And KYOWA HAKKO
- Zeria Pharmaceutical Enters Into Co-Development Agreement With Kyowa Hakko Kogyo
- Licensing Agreements
- Tillotts Pharma Enters Into Licensing Agreement With The School of Pharmacy
- Zeria Pharmaceutical Enters Into License Agreement With SK Chemicals For PROMAC
- Zeria Pharmaceutical Enters Into Licensing Agreement With Eli Lilly
- Tillotts Pharma Enters Into License Agreement With Zeria Pharmaceutical
- Acquisition
- Zeria Pharmaceutical Acquires Biofac
- Zeria Pharmaceutical Acquires Tillotts Pharma
- Zeria Pharmaceutical Acquires lona International
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Zeria Pharmaceutical Co Ltd - Pipeline by Therapy Area and Indication, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline by Stage of Development, H2 2011
- Zeria Pharmaceutical Co Ltd - Filed, H2 2011
- Zeria Pharmaceutical Co Ltd - Phase III, H2 2011
- Zeria Pharmaceutical Co Ltd - Phase II, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Therapeutic Class, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Target, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Route of Administration, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Molecule Type, H2 2011
- Zeria Pharmaceutical Co Ltd - Recent Pipeline Updates, H2 2011
- Zeria Pharmaceutical Co Ltd - Dormant Developmental Projects, 2010
- Zeria Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2010
- Zeria Pharmaceutical Co Ltd, Other Locations
- Zeria Pharmaceutical Co Ltd, Subsidiaries
- Zeria Pharmaceutical Co Ltd, Deals Summary
- HemCon Medical Technologies Signs Licensing Agreement With Zeria Pharmaceuticals
- Augurix Enters Into Co-Marketing Agreement With Tillotts Pharma
- Cambrex Enters Into Co-Development Agreement With Tillotts Pharma
- Zeria Pharmaceutical Enters Into Agreement With Astellas Pharma
- Tillotts Pharma Enters Into Research Collaboration Agreement With University of London
- Zeria Pharmaceutical Enters Into Co-Development Agreement With TMRC
- Tillotts Pharma Enters Into Development And Marketing Agreement With Zeria And KYOWA HAKKO
- Zeria Pharmaceutical Enters Into Co-Development Agreement With Kyowa Hakko Kogyo
- Tillotts Pharma Enters Into Licensing Agreement With The School of Pharmacy
- Zeria Pharmaceutical Enters Into License Agreement With SK Chemicals For PROMAC
- Zeria Pharmaceutical Enters Into Licensing Agreement With Eli Lilly
- Tillotts Pharma Enters Into License Agreement With Zeria Pharmaceutical
- Zeria Pharmaceutical Acquires Biofac
- Zeria Pharmaceutical Acquires Tillotts Pharma
- Zeria Pharmaceutical Acquires lona International
- List of Figures
- Zeria Pharmaceutical Co Ltd - Pipeline by Therapy Area and Indication, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline by Stage of Development, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Therapeutic Class, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Target, H2 2011
- Zeria Pharmaceutical Co Ltd - Pipeline By Route of Administration, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
